IP Library Granted Patent US 11,234,959
Granted Patent B2
US 11,234,959 · App. 16/347,155 · Granted Feb 1, 2022

Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema

Inventors: Feriel Hacini-Rachinel (Biot, FR); André Jomard (Saint Vallier de Thiey, FR); Jean Jacovella (Antibes, FR); Emmanuel Vial (Nice, FR)
Assignee: GALDERMA HOLDING SA
A61K31/365A61K9/0014A61K9/06A61K47/02A61K47/10A61K47/14A61K47/183A61P17/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,234,959
App. No.
16/347,155
Granted
Feb 1, 2022
Kind
B2
Abstract

The present invention relates to a pharmaceutical composition comprising a compound of the avermectin family, preferably ivermectin, in a pharmaceutically acceptable carrier, for use in the treatment and/or prevention of hand eczema.

Claims (49)

1. A method of treating and/or preventing hand eczema, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising:

0.3% to 2% by weight, relative to the total weight of the composition, of ivermectin; and

a pharmaceutically acceptable carrier.

2. The method according to claim 1 , wherein the hand eczema is chronic hand eczema.

3. The method according to claim 1 , wherein the administering is topical application.

4. The method according to claim 1 , wherein the composition is in the form of an emulsion, of a cream, of a lotion type, of a gel or of a solution.

5. The method according to claim 1 , wherein the composition comprises from 1% to 2%, by weight, of ivermectin, relative to the total weight of the composition.

6. The method according to claim 1 , wherein the composition comprises about 0.3, 1, or 2%, by weight, of ivermectin, relative to the total weight of the composition.

7. The method according to claim 1 , wherein the composition comprises:

Ivermectin 1.0

Glycerol 4.0

Acrylate C10-30 alkyl acrylate crosspolymer 0.2

Methyl para-hydroxybenzoate 0.2

Disodium EDTA 0.05

Citric acid monohydrate 0.05

Isopropyl palmitate 4.0

Cetyl alcohol 3.5

Stearyl alcohol 2.5

Oleyl alcohol 2.0

Ceteareth-20 3.0

Sorbitan monostearate 2.0

Dimethicone 200 20 cs 0.5

Propyl para-hydroxybenzoate 0.1

Propylene glycol 2.0

Phenoxyethanol 1.0

10% sodium hydroxide qs pH

water qs 100,

as % by weight relative to the total weight of the composition.

8. The method according to claim 1 , wherein the composition comprises:

Ivermectin 0.3

Glycerol 4.0

Acrylate C10-30 alkyl acrylate crosspolymer 0.2

Methyl para-hydroxybenzoate 0.2

Disodium EDTA 0.05

Citric acid monohydrate 0.05

Isopropyl palmitate 4.0

Cetyl alcohol 3.5

Stearyl alcohol 2.5

Oleyl alcohol 2.0

Ceteareth-20 3.0

Sorbitan monostearate 2.0

Dimethicone 200 20 cs 0.5

Propyl para-hydroxybenzoate 0.1

Propylene glycol 2.0

Phenoxyethanol 1.0

10% sodium hydroxide qs pH

water qs 100,

as % by weight relative to the total weight of the composition.

9. The composition of claim 1 , wherein the concentration of ivermectin is 0.3% or 1.0% by weight, relative to the total weight of the composition.

Assignments (3)
CHANGE OF ADDRESS Recorded Jun 27, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 061113/0710 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2021
From: HACINI-RACHINEL, FERIEL; JOMARD, ANDRÉ; JACOVELLA, JEAN; VIAL, EMMANUEL
To: NESTLÉ SKIN HEALTH SA
Reel/Frame 058217/0281 →
CHANGE OF NAME Recorded Nov 27, 2021
From: NESTLÉ SKIN HEALTH SA
To: GALDERMA HOLDING SA
Reel/Frame 058217/0299 →